EA004543B1 - Применение треосульфана для подготовки пациентов перед трансплантацией костного мозга или трансплантацией стволовых клеток крови - Google Patents

Применение треосульфана для подготовки пациентов перед трансплантацией костного мозга или трансплантацией стволовых клеток крови Download PDF

Info

Publication number
EA004543B1
EA004543B1 EA200200535A EA200200535A EA004543B1 EA 004543 B1 EA004543 B1 EA 004543B1 EA 200200535 A EA200200535 A EA 200200535A EA 200200535 A EA200200535 A EA 200200535A EA 004543 B1 EA004543 B1 EA 004543B1
Authority
EA
Eurasian Patent Office
Prior art keywords
use according
treosulfan
body surface
days
pharmaceutical composition
Prior art date
Application number
EA200200535A
Other languages
English (en)
Russian (ru)
Other versions
EA200200535A1 (ru
Inventor
Йоахим Баумгарт
Original Assignee
Медак Гезелльшафт Фюр Клинише Шпециальпрепарате Мбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Медак Гезелльшафт Фюр Клинише Шпециальпрепарате Мбх filed Critical Медак Гезелльшафт Фюр Клинише Шпециальпрепарате Мбх
Publication of EA200200535A1 publication Critical patent/EA200200535A1/ru
Publication of EA004543B1 publication Critical patent/EA004543B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Materials For Medical Uses (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Saccharide Compounds (AREA)
EA200200535A 1999-11-05 2000-11-03 Применение треосульфана для подготовки пациентов перед трансплантацией костного мозга или трансплантацией стволовых клеток крови EA004543B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19953517A DE19953517C1 (de) 1999-11-05 1999-11-05 Verwendung von Treosulfan zur Konditionierung von Patienten vor Knochemarktransplantation oder Blutstammzelltransplantation
PCT/EP2000/010871 WO2001032154A2 (de) 1999-11-05 2000-11-03 Verwendung von treosulfan zur konditionierung von patienten vor knochenmarktransplantation oder blutstammzelltransplantation

Publications (2)

Publication Number Publication Date
EA200200535A1 EA200200535A1 (ru) 2002-10-31
EA004543B1 true EA004543B1 (ru) 2004-06-24

Family

ID=7928187

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200200535A EA004543B1 (ru) 1999-11-05 2000-11-03 Применение треосульфана для подготовки пациентов перед трансплантацией костного мозга или трансплантацией стволовых клеток крови

Country Status (16)

Country Link
US (1) US7199162B1 (cg-RX-API-DMAC7.html)
EP (1) EP1227808B1 (cg-RX-API-DMAC7.html)
JP (1) JP4846151B2 (cg-RX-API-DMAC7.html)
AT (1) ATE251455T1 (cg-RX-API-DMAC7.html)
AU (1) AU777527B2 (cg-RX-API-DMAC7.html)
BG (1) BG65845B1 (cg-RX-API-DMAC7.html)
CA (1) CA2389896C (cg-RX-API-DMAC7.html)
CZ (1) CZ299701B6 (cg-RX-API-DMAC7.html)
DE (2) DE19953517C1 (cg-RX-API-DMAC7.html)
EA (1) EA004543B1 (cg-RX-API-DMAC7.html)
ES (1) ES2208435T3 (cg-RX-API-DMAC7.html)
HU (2) HU227332B1 (cg-RX-API-DMAC7.html)
NO (2) NO329616B1 (cg-RX-API-DMAC7.html)
PL (1) PL212132B1 (cg-RX-API-DMAC7.html)
UA (1) UA73961C2 (cg-RX-API-DMAC7.html)
WO (1) WO2001032154A2 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10237146A1 (de) * 2002-08-13 2004-03-04 Medac Gesellschaft für klinische Spezialpräparate mbH Verwendung von Treosulfan und Derivaten davon zur Behandlung der Multiplen Sklerose
JP7431815B2 (ja) * 2018-09-26 2024-02-15 メダック ゲゼルシャフト フィア クリニッシェ スペツィアルプレパラーテ ミット ベシュレンクタ ハフトゥンク トレオスルファンの結晶形
PT4257122T (pt) 2018-09-26 2026-06-08 Medac Ges Fr Klinische Spezialprparate Mbh Liofilizado de treossulfano
EP3856252A1 (en) 2018-09-26 2021-08-04 medac Gesellschaft für klinische Spezialpräparate mbH Solution comprising treosulfan

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376546A (en) * 1991-11-04 1994-12-27 Xoma Corporation Analogs of ribosome-inactivating proteins
DE4421391C1 (de) * 1994-06-18 1995-11-30 Gsf Forschungszentrum Umwelt Verwendung von Antikörpern gegen T-Zellen zur verlängerten Immunsuppression
WO2000045842A2 (en) * 1999-02-04 2000-08-10 The General Hospital Corporation Methods for human allografting

Also Published As

Publication number Publication date
CA2389896A1 (en) 2001-05-10
ATE251455T1 (de) 2003-10-15
CZ20021562A3 (cs) 2002-10-16
BG65845B1 (bg) 2010-03-31
EP1227808B1 (de) 2003-10-08
NO2019032I1 (no) 2019-07-23
DE50004024D1 (de) 2003-11-13
EP1227808A2 (de) 2002-08-07
CZ299701B6 (cs) 2008-10-22
AU1391801A (en) 2001-05-14
WO2001032154A2 (de) 2001-05-10
DE19953517C1 (de) 2001-08-09
NO20022109L (no) 2002-07-01
US7199162B1 (en) 2007-04-03
PL212132B1 (pl) 2012-08-31
NO329616B1 (no) 2010-11-22
ES2208435T3 (es) 2004-06-16
AU777527B2 (en) 2004-10-21
HUP0203277A2 (en) 2003-01-28
PL356240A1 (en) 2004-06-28
BG106772A (bg) 2003-02-28
NO20022109D0 (no) 2002-05-02
CA2389896C (en) 2007-04-10
UA73961C2 (uk) 2005-10-17
WO2001032154A3 (de) 2002-01-24
JP2003513034A (ja) 2003-04-08
JP4846151B2 (ja) 2011-12-28
EA200200535A1 (ru) 2002-10-31
HU227332B1 (en) 2011-03-28
HUS1900041I1 (hu) 2019-10-28

Similar Documents

Publication Publication Date Title
Inamura et al. Prolongation of skin allograft survival in rats by a novel immunosuppressive agent, FK 506
US12343342B2 (en) Methods for treating soft tissue sarcoma
EP0344880B1 (en) Pharmaceutical compositions with anti-cancer activity
CN100479814C (zh) 促淋巴细胞归巢剂在制备用于治疗移植物功能恢复延迟的药物中的用途
DE69124380T2 (de) Verfahren und zusammensetzungen für die behandlung durch t-zellen vermittelter krankheiten
US7199162B1 (en) Use of treosulfan for patient conditioning before bone marrow or blood stem cell transplantation
EP0972519B1 (en) Immune tolerance inducers
JP3962097B2 (ja) 免疫抑制剤による副作用の軽減剤
JP2007527851A (ja) 乾癬の治療薬を製造するためのカハラリド化合物の使用
JP3064815B2 (ja) ミエローマ系腫瘍抗癌剤
Wilson et al. Weekly cyclophosphamide and alternate-day prednisone: an effective secondary therapy in multiple myeloma
JPH09506115A (ja) 細胞毒性薬の副作用を軽減するためのトランスフェリン組成物
CN102614180A (zh) 伊曲康唑在制备治疗多发性骨髓瘤药物中的应用
KR100318519B1 (ko) 우라실을 유효성분으로 함유하는 관절염치료제
RU2123348C1 (ru) Противолучевое средство
Veys et al. Recombinant interferon gamma in rheumatoid arthritis. A double-blind study comparing Immuneron (recombinant interferon gamma) with placebo
JPH04327541A (ja) 拒絶反応による移植臓器障害治療剤
JP2800412B2 (ja) 免疫抑制作用増強剤
KR20220082862A (ko) 혈액 악성 종양을 치료하기 위한 병용 요법
EP0784976A1 (en) Immunosuppressive-activity potentiating compositions containing ascorbyl tocopheryl phosphoric acid diesters
Taguchi et al. Combination effect of human recombinant TNF (PT-050) and antitumor drugs
Muller The Influence of Liver Extract and Acute Infection on Reticulocytes and Bone Marrow of Pigeons
Kurtzberg et al. Results of the cord blood transplantation study (COBLT): Clinical outcomes of unrelated donor umbilical cord blood transplantation in pediatric patients with inborn errors of metabolism
Kohn et al. Busulfan dose escalation to increase gene marking of hematopoietic stem cells by lentiviral vectors in infant rhesus monkeys
WO1990001319A1 (en) Use of castanospermine as an anti-inflammatory and immunosuppressant agent

Legal Events

Date Code Title Description
MK4A Patent expired

Designated state(s): AM AZ BY KZ KG MD TJ TM RU